Sjögren's Syndrome in Inflammatory Rheumatic Diseases: Analysis of the Leukocyte Protein Calprotectin in Plasma and Saliva

References

• Workshop on Diagnostic Criteria for Sjögren's syndrome. II. Manual of methods and procedures. Clin Exp Rheumatol 1989; 7(2)213–19
   Google Scholar
• Atkinson J C, Travis W D, Slocum L, Ebbs W L, Fox P C. Serum anti-SS-B/La and IgA rheumatoid factor are markers of salivary gland disease activity in primary Sjögren's syndrome. Arthritis Rheum 1992; 35: 1368–72
   PubMed Web of Science ®Google Scholar
• Jonsson R, Kroneld U, Bäckman K, Magnusson B, Tarkowski A. Progression of sialadenitis in Sjögren's syndrome. Br J Rheumatol 1993; 32: 578–81
   PubMedGoogle Scholar
• Konttinen Y T, Kulomaa M, Malmström M, Kilpi A, Reitamo S. Lactoferrin in Sjögren's syndrome. Arthritis Rheum 1984; 27: 462–67
   PubMedGoogle Scholar
• Horsfall A C, Rose L M, Maini R N. Autoantibody synthesis in salivary glands of Sjögren's syndrome patients. J Autoimmun 1989; 2: 559–68
   PubMedGoogle Scholar
• Michalski J P, Daniels T E, Talal N, Grey H M. Beta2 microglobulin and lymphocytic infiltration in Sjögren's syndrome. New Engl J Med 1975; 293: 1228–31
   PubMed Web of Science ®Google Scholar
• Fagerhol M K, Andersson K B, Naess-Andresen C-F, Brandtzaeg P, Dale I. Calprotectin (= The L1 Leukocyte Protein). Stimulus response coupling: The role of intracellular calcium-binding proteins, V L Smith, J R Dedman. CRC Press, Boca Raton 1990; 187–210
   Google Scholar
• Dale I. Plasma levels of the calcium-binding L1 leukocyte protein: Standardization of blood collection and evaluation of reference intervals in healthy controls. Scand J Clin Lab Invest 1990; 50: 837–41
   PubMed Web of Science ®Google Scholar
• Berntzen H B, Endresen G KM, Fagerhol M K, Spiechowicz J, Mowinckel P. Calprotectin (the L1 protein) during surgery in patients with rheumatoid arthritis. Scand J Clin Lab Invest 1991; 51: 643–50
   PubMed Web of Science ®Google Scholar
• Fagerhol M K, Dale I, Andersson T. Release and quantitation of a leukocyte derived protein (L1). Scand J Haematol 1980; 24: 393–8
   Google Scholar
• Sander J, Fagerhol M K, Bakken J S, Dale I. Plasma levels of the leucocyte L1 protein in febrile conditions: relation to aetiology, number of leucocytes in blood, blood sedimentation reaction and C-reactive protein. Scand J Clin Lab Invest 1984; 44(4)357–62
   PubMed Web of Science ®Google Scholar
• Semb A G, Gabrielsen T O, Halstensen T S, Fagerhol M K, Brandtzaeg P, Vaage J. Cardiac surgery and distribution of the leukocyte L1 protein — calprotectin. Eur J Cardiothorac Surg 1991; 5: 363–7
   PubMedGoogle Scholar
• Berntzen H B, Munthe E, Fagerhol M K. The major leucocyte protein LI as an indicator of inflammatory joint disease. Scand J Rheumatol 1988; 251–56, suppl 76
   Google Scholar
• Berntzen H B, Munthe E, Fagerhol M K. A longitudinal study of the leucocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989; 16(11)1416–20
   PubMedGoogle Scholar
• Brun J G, Haga H-J, Bøe E, Kallay I, Lekven C, Berntzen H B, Fagerhol M K. Calprotectin in patients with rheumatoid arthritis: Relation to clinical and laboratory variables of disease activity. J Rheumatol 1992; 19: 859–62
   PubMed Web of Science ®Google Scholar
• Haga H-J, Brun J G, Berntzen H B, Cervera R, Khamashta M, Hughes G RV. Calprotectin in patients with systemic lupus erythematosus: Relation to clinical and laboratory parameters of disease activity. Lupus 1993; 2: 47–50
   PubMed Web of Science ®Google Scholar
• Berntzen H B, Ölmez Ü, Fagerhol M K, Munthe E. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991; 20: 74–82
   PubMed Web of Science ®Google Scholar
• Brun J G, Jonsson R, Haga H-J. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol, (in press)
   Google Scholar
• Cuida M, Brun J G, Jacobsen H, Rygh T, Johannesen A C, Jonsson R. Calprotectin in chronically inflamed salivary glands and saliva. Proceedings of the IVth International Symposium on Sjögren's syndrome, Tokyo, August 11–13, 1993
   Google Scholar
• Vitali C, Bombardierl S, Moutsopoulos H M, Balestrieri G, Bencivelli W, Bernstein R M, et al. Preliminary criteria for the classification of Sjögren's syndrome. Arthritis Rheum 1993; 36: 340–7
   PubMed Web of Science ®Google Scholar
• Røseth A G, Fagerhol M K, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793–8
   PubMed Web of Science ®Google Scholar
• Norusis M J. SPSS/PC+ V3.0 Update Manual. SPSS Inc., Chicago 1988
   Google Scholar
• Steinbakk M, Naess-Andresen C-F, Lingaas E, Dale I, Brandtzaeg P, Fagerhol M K. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990; 336: 763–5
   PubMed Web of Science ®Google Scholar
• Müller F, Frøland S S, Brandtzaeg P, Fagerhol M K. Oral candidiasis is associated with low levels of parotid calprotectin in idividuals with infection due to human immunodeficiency virus. Clinical Infectious Diseases 1993; 16: 301–2
   PubMedGoogle Scholar
• Eversole L R, Miyasaki K T, Christensen R E. Keratinocyte expression of calprotectin in oral inflammatory mucosal diseases. J Oral Pathol Med 1993; 22: 303–7
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P, Dale I, Fagerhol M K. Distribution of a formalinresistant myelomonocytic antigen (L1) in human tissues. 2. Normal and aberrant occurence in various epithelia. Am J Clin Pathol 1987; 87: 700–7
   PubMed Web of Science ®Google Scholar